Literature DB >> 11380839

Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years.

J L Bosmans1, P Holvoet, S E Dauwe, D K Ysebaert, T Chapelle, A Jürgens, V Kovacic, E A Van Marck, M E De Broe, G A Verpooten.   

Abstract

BACKGROUND: Previous studies reported a significant association between hyperlipidemia of the recipient and chronic allograft nephropathy (CAN). However, the nature and the pathogenic mechanism of circulating lipid abnormalities in CAN remain unclear.
METHODS: In a prospective study of 50 consecutive adult recipients of a cadaveric renal allograft, we investigated the impact of lipid abnormalities on the outcome of the graft at 1 1/2 years. Besides morphometric analysis of implantation and protocol biopsies, clinical and biochemical variables were studied at three-month intervals. Plasma concentrations of oxidized low-density lipoprotein (OxLDL) were determined by means of enzyme-linked immunosorbent assay. Immunohistochemical staining for OxLDL and macrophages was performed on paired renal biopsies. Study end points were the fractional interstitial volume and the 24-hour creatinine clearance at 11/2 years.
RESULTS: High-density lipoprotein (HDL) cholesterol of the recipient < or =47 mg/dL was a risk factor for the functional (RR = 1.56; 95% CI, 0.978 to 2.497) and the morphological (RR = 2.75; 95% CI, 1.075 to 7.037) outcome of the graft, mainly in patients without acute rejection (RR = 2.03; 95% CI, 1.13 to 3.65, and RR = 4.67; 95% CI, 1.172 to 18.582, respectively). Interstitial accumulation of OxLDL was inversely associated with HDL cholesterol (R = -0.476, P = 0.019), and was associated with a higher density of tubulointerstitial macrophages (R = 0.656, P = 0.001) and a higher fractional interstitial volume at 11/2 years (P = 0.049).
CONCLUSION: Decreased HDL cholesterol levels of the recipient adversely affect the outcome of renal allografts through the accumulation of OxLDL in the renal interstitium of the graft. Interstitial accumulation of OxLDL was associated with the presence of macrophages and the development of interstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380839     DOI: 10.1046/j.1523-1755.2001.00752.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

Review 1.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

Review 2.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

3.  Perindopril attenuates renal tubulointerstitium injury by inhibiting scavenger receptor A over-expression in diabetic rats.

Authors:  L Sun; J H Wen; H L Sun; X C Shu; F Hu; D C Yin; Q Yang; Y J Zeng; Y Sun; L Liu
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

Review 4.  Post-transplant dyslipidemia: Mechanisms, diagnosis and management.

Authors:  Arnav Agarwal; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2016-03-24

5.  Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.

Authors:  Hyun Ju Kim; Hamid Moradi; Jun Yuan; Keith Norris; Nosratola D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-08

6.  Dietary conjugated linoleic acid renal benefits and possible toxicity vary with isomer, dose and gender in rat polycystic kidney disease.

Authors:  Malcolm R Ogborn; Evan Nitschmann; Aviva Goldberg; Neda Bankovic-Calic; Hope A Weiler; Harold M Aukema
Journal:  Lipids       Date:  2008-07-16       Impact factor: 1.880

7.  Dietary flax oil reduces renal injury, oxidized LDL content, and tissue n-6/n-3 FA ratio in experimental polycystic kidney disease.

Authors:  Malcolm R Ogborn; Evan Nitschmann; Neda Bankovic-Calic; Hope A Weiler; Harold Aukema
Journal:  Lipids       Date:  2002-11       Impact factor: 1.880

8.  CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.

Authors:  Paul Gutwein; Mohamed Sadek Abdel-Bakky; Anja Schramme; Kai Doberstein; Nicole Kämpfer-Kolb; Kerstin Amann; Ingeborg A Hauser; Nicholas Obermüller; Christine Bartel; Abdel-Aziz H Abdel-Aziz; El Sayed M El Sayed; Josef Pfeilschifter
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

9.  Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-κB improves renal recovery in chronic kidney disease.

Authors:  Alejandro R Chade; Maxx L Williams; Jason E Engel; Erika Williams; Gene L Bidwell
Journal:  Am J Physiol Renal Physiol       Date:  2020-06-15

10.  Oxidized LDL Modifies the Association between Proteinuria and Deterioration of Kidney Function in Proteinuric Diabetic Kidney Disease.

Authors:  Stefanos Roumeliotis; Panagiotis I Georgianos; Athanasios Roumeliotis; Theodoros Eleftheriadis; Aikaterini Stamou; Vangelis G Manolopoulos; Stylianos Panagoutsos; Vassilios Liakopoulos
Journal:  Life (Basel)       Date:  2021-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.